Biologic therapeutic approach to modulating T cell inflammatory diseases by expressing isolated or recombinant combinations of WSX-1 or gp130 polypeptide with interacting proteins (such as p28, EBI3, Il-27) to inhibit pathological T cell development.
Problem:
The interleukin-27 receptor (WSX -1) is a heterodimeric type I cytokine receptor for interleukin-27 comprising the WSX-1 (alpha subunit) and glycoprotein 130 and is essential for initiation of Th1 cell differentiation.
Solution:
Dr. Christopher Hunter discovered that WSX-1 signaling has a negative effect on T cell responses. In fact, a WSX-1 fusion protein or soluble p28 (Il-30) is able to enhance the ability of Il-27 to inhibit T cell production of Il-2 and IFNγ as well as the T cell subset of Il-17 producing T cells, which is a major pathological T cell subset. Penn has pending proprietary rights to various polypeptide compositions which encompass this technology.
Advantages:
- Il-27 is a potent immune suppressive cytokine when given exogenously in multiple experimental models of immune mediated disease with clinical utility.
- Unlike other cytokines, such as type I IFNs or IL-12, there is no overt toxicity when IL-27 is used to treat mice.
Stage of Development:
Preclinical proof of concept
Intellectual Property:
Pending application in Canada; issued patents in US, European Union, and Mexico
Case ID:
S4226-tpNCS
Web Published:
3/6/2020
Patent Information:
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |